Regen BioPharma, Inc. to Discuss Plans to Move Forward With HemaXellerate Into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
Regen BioPharma, Inc. to Discuss Plans to Move Forward With HemaXellerate Into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
Regen BioPharma, Inc. invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Regen BioPharma, Inc. 邀請個人和機構投資者以及顧問和分析師參加其在新興增長會議上的實時互動演講。
SAN DIEGO, April 2, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on April 4, 2024 (
聖地亞哥，2024 年 4 月 2 日 /PRNewswire/ — Regen BioPharma, Inc.（場外交易代碼：RGBP）（場外交易代碼：RGBP），一家推進涵蓋細胞療法、RNA疫苗、RNA和DNA療法以及小分子藥物的多元化臨床前產品線的生物技術公司，將在2024年4月4日的新興增長會議上發表演講（
This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to address as many of them as possible.
這項實時互動的在線活動將使現有股東和投資界有機會與公司首席執行官戴維·庫斯博士進行實時互動。請在活動期間提出您的問題，庫斯博士和他的團隊將盡最大努力解決儘可能多的問題。
"We plan to use this time to update our shareholders on current plans and opportunities to advance our most advanced asset, HemaXellerate, into Phase 1 trials," says Dr. David Koos, CEO and Chairman of the Company.
該公司首席執行官兼董事長戴維·庫斯博士說：“我們計劃利用這段時間向股東介紹當前的計劃和機會，將我們最先進的資產HemaXellerate推進第一階段試驗。”
Regen BioPharma, Inc. will be presenting at 4:10-4:20 Eastern time on Thursday April 4, 2024. Please register here to ensure you are able to attend the conference and receive any updates that are released
Regen BioPharma, Inc. 將於美國東部時間2024年4月4日星期四 4:10-4:20 發表演講。請在此處註冊，以確保您能夠參加會議並接收已發佈的任何更新
If attendees are not able to join the event live on the day of the conference an archived webcast will also be made available on EmergingGrowth.com.
如果與會者無法在會議當天直播參加活動，還將在EmergingGrowth.com上提供存檔的網絡直播。
About the Emerging Growth Conference
關於新興增長會議
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
新興增長會議是上市公司在辦公室方便地以省時的方式向投資界展示和傳達其新產品、服務和其他重大公告的有效方式。
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.
會議的重點和覆蓋範圍包括各個成長領域的公司，擁有強大的管理團隊、創新的產品和服務、重點的戰略、執行以及長期增長的整體潛力。其受衆可能包括成千上萬的個人和機構投資者，以及投資顧問和分析師。
About Regen BioPharma Inc.:
關於 Regen BioPharma Inc.：
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at
Regen BioPharma, Inc. 是一家上市的生物技術公司（PINK：RGBP）和（PINK：RGBPP）。該公司專注於免疫學和免疫療法領域。該公司專注於通過臨床前和I/II期臨床試驗快速推進新技術。目前，該公司專注於治療癌症和自身免疫性疾病的mRNA和小分子療法。有關 Regen BioPharma 的更多信息，請訪問
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
免責聲明： 本新聞公告可能包含前瞻性陳述。前瞻性陳述本質上受風險和不確定性的影響，其中一些風險和不確定性無法預測或量化。未來事件和實際結果可能與前瞻性陳述中列出、考慮或作爲基礎的事件和實際業績存在重大差異。前瞻性陳述所涉及的風險和不確定性包括但不限於政府監管、競爭和其他重大風險的影響。
CONTACT INFORMATION:
聯繫信息：
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: [email protected]
Regen BioPharma Inc.
大衛·庫斯博士
董事長兼首席執行官
+1-619-722-5505 電話
+1-619-330-2328 傳真
電子郵件：[電子郵件保護]
Twitter (now X):
推特（現爲 X）：
SOURCE Regen BioPharma, Inc.
來源 Regen BioPharma, Inc.